Unique changes in DNA structure found in each family, affected genes important to neuronal function

INDIANAPOLIS, June 16 (UPI) -- U.S. drug maker Eli Lilly and Co. said it stopped its Phase II study of a promising drug to slow Alzheimer's disease over concerns about potential liver damage.

Title: Alzheimer's Disease Set to ExplodeCategory: Health NewsCreated: 6/12/2007 12:00:00 AMLast Editorial Review: 6/12/2007 12:00:00 AM

Eli Lilly and Co. said Thursday that it stopped a mid-stage clinical trial of an experimental Alzheimer's disease drug because of potential side effects on patients' livers.

Lilly terminated a midstage clinical trial of an experimental Alzheimer's disease drug after four patients had abnormal liver biochemical tests.